Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Nov;17(6):1523-4. doi: 10.1208/s12248-015-9822-9. No abstract available.

2.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Sep;17(5):1144-56. doi: 10.1208/s12248-015-9782-0. Epub 2015 May 13. Erratum in: AAPS J. 2015 Nov;17(6):1523-4.

3.

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.

Kang DW, Jadin L, Nekoroski T, Drake FH, Zepeda ML.

Drug Deliv Transl Res. 2012 Aug;2(4):254-64. doi: 10.1007/s13346-012-0065-3.

PMID:
25787031
4.

Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.

Dodds RA, James IE, Rieman D, Ahern R, Hwang SM, Connor JR, Thompson SD, Veber DF, Drake FH, Holmes S, Lark MW, Gowen M.

J Bone Miner Res. 2001 Mar;16(3):478-86.

5.

Biosynthesis and processing of cathepsin K in cultured human osteoclasts.

Rieman DJ, McClung HA, Dodds RA, Hwang SM, Holmes MW, James IE, Drake FH, Gowen M.

Bone. 2001 Mar;28(3):282-9.

PMID:
11248658
6.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M.

J Pharmacol Exp Ther. 1999 Nov;291(2):612-7.

PMID:
10525079
7.
8.

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Huffman WF, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.

PMID:
10406646
9.

The collagenolytic activity of cathepsin K is unique among mammalian proteinases.

Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM.

J Biol Chem. 1998 Nov 27;273(48):32347-52.

10.

A novel human bone marrow stroma-derived cell line TF274 is highly osteogenic in vitro and in vivo.

Prabhakar U, James IE, Dodds RA, Lee-Rykaczewski E, Rieman DJ, Lipshutz D, Trulli S, Jonak Z, Tan KB, Drake FH, Gowen M.

Calcif Tissue Int. 1998 Sep;63(3):214-20.

PMID:
9701625
11.

Design of potent and selective human cathepsin K inhibitors that span the active site.

Thompson SK, Halbert SM, Bossard MJ, Tomaszek TA, Levy MA, Zhao B, Smith WW, Abdel-Meguid SS, Janson CA, D'Alessio KJ, McQueney MS, Amegadzie BY, Hanning CR, DesJarlais RL, Briand J, Sarkar SK, Huddleston MJ, Ijames CF, Carr SA, Garnes KT, Shu A, Heys JR, Bradbeer J, Zembryki D, Lee-Rykaczewski L, James IE, Lark MW, Drake FH, Gowen M, Gleason JG, Veber DF.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14249-54.

12.

Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.

Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M.

J Bone Miner Res. 1997 Sep;12(9):1396-406.

13.

The new partnership of genomics and chemistry for accelerated drug development.

Veber DF, Drake FH, Gowen M.

Curr Opin Chem Biol. 1997 Aug;1(2):151-6. Review.

PMID:
9667859
14.

Cloning and characterization of a novel integrin beta3 subunit.

Kumar CS, James IE, Wong A, Mwangi V, Feild JA, Nuthulaganti P, Connor JR, Eichman C, Ali F, Hwang SM, Rieman DJ, Drake FH, Gowen M.

J Biol Chem. 1997 Jun 27;272(26):16390-7.

15.

Genomic organization and chromosome localization of the human cathepsin K gene (CTSK).

Rood JA, Van Horn S, Drake FH, Gowen M, Debouck C.

Genomics. 1997 Apr 15;41(2):169-76.

PMID:
9143491
16.

Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.

Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA.

J Biol Chem. 1996 May 24;271(21):12517-24.

17.

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.

Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M.

J Biol Chem. 1996 May 24;271(21):12511-6.

18.

DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2.

Taagepera S, Rao PN, Drake FH, Gorbsky GJ.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8407-11.

19.
20.

Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy.

Petrov P, Drake FH, Loranger A, Huang W, Hancock R.

Exp Cell Res. 1993 Jan;204(1):73-81.

PMID:
8380143
22.
23.
24.

Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.

Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK.

Cancer Res. 1990 May 15;50(10):2901-8.

25.

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.

Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK.

Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5.

26.

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK.

Biochemistry. 1989 Oct 3;28(20):8154-60.

PMID:
2557897
27.

Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.

Mattern MR, Tan KB, Zimmerman JP, Mong SM, Bartus JO, Hofmann GA, Drake FH, Johnson RK, Crooke ST, Mirabelli CK.

Anticancer Drug Des. 1989 Aug;4(2):107-24.

PMID:
2478139
28.

In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK.

Cancer Res. 1989 May 15;49(10):2578-83.

29.

Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST, et al.

J Biol Chem. 1987 Dec 5;262(34):16739-47.

30.

Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.

Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK, Crooke ST.

Mol Pharmacol. 1987 Jul;32(1):17-25.

PMID:
3037302

Supplemental Content

Loading ...
Support Center